drugset / Trial / NCT02013089
A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Hypothesis: Different patients have different biomarkers, if doctors know about the biomarkers of patients; they may be able to prescribe a regimen that is better suited to the patient's specific needs. This is a pilot study. Here, we used whole exon sequencing and Integrated genomic network analysis to identify the biomarker or gene. We aimed to learn if the drug chosen based on biomarkers can help to control metastatic gastrointestinal cancer who had failed from all standard and available regimens.
Timeline
- Start
- 2013-12
- Primary completion
- 2017-05
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Gefitinib | Small molecule | 250 mg | Oral |
| Subject | Imatinib | Small molecule | 400 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | — |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |
| Subject | Vandetanib | Small molecule | 300 mg | Oral |